2h
Zacks Investment Research on MSNOrganon (OGN) Advances While Market Declines: Some Information for InvestorsOrganon (OGN) closed at $15.70 in the latest trading session, marking a +0.51% move from the prior day. The stock outperformed the S&P 500, which registered a daily loss of 1.07%. Meanwhile, the Dow ...
AlphaQuest LLC lowered its stake in Organon & Co. (NYSE:OGN – Free Report) by 76.1% during the 4th quarter, according to the ...
We recently published a list of 10 Deep Value Stocks to Buy Now. In this article, we are going to take a look at where ...
Larson Financial Group LLC grew its holdings in Organon & Co. (NYSE:OGN – Free Report) by 345.4% in the fourth quarter, ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
An acclaimed original graphic novel is making a welcome return thanks to Papercutz, and we’ve got your exclusive first look and details right here! Papercutz is pulling the curtain back on the ...
Shares of pharmaceutical company Organon (NYSE:OGN) jumped 12.5% in the morning session after the company reported fourth-quarter 2024 results that topped analysts' revenue and EPS expectations.
JERSEY CITY, N.J., March 08, 2025--Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, today announced results from an analysis of the Phase 3 ADORING 3 open-label ...
Organon (OGN) announced results from an analysis of the Phase 3 ADORING 3 open-label, long-term extension study evaluating VTAMA cream, 1% once ...
In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Organon (OGN – Research Report), with a price target of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results